Full-Time

Global Development Lead Senior Director

Internal Medicine, Non-MD

Updated on 9/12/2026

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$214.9k - $358.1k/yr

+ 22.5% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Cambridge, MA, USA + 7 more

More locations: Collegeville, PA, USA | Tadworth, UK | Bothell, WA, USA | Pearl River, NY, USA | La Jolla, San Diego, CA, USA | Groton, CT, USA | New York, NY, USA

Hybrid

Hybrid role requiring residence within commuting distance and an average of 2.5 on-site days per week. Up to 30% travel may be required.

PhD

Category
Biology & Biotech (1)

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A PhD or PharmD is required.
  • Background in chronic weight management, endocrinology, or internal medicine with experience in Phase 1–3 clinical development and translational medicine is required.
  • At least 8 years of relevant experience and a successful track record in academia and/or the biopharmaceutical industry in clinical research and development are required.
  • Extensive knowledge of clinical development, global and regional regulation, ICH/GCP, and adverse-event management is required.
  • Demonstrated clinical/medical, administrative, and project-management capabilities are required.
  • Effective verbal and written communication skills for working with individuals inside and outside the organization are required.
  • Demonstrated experience managing and training large teams in clinical development is required.
  • The candidate must demonstrate diverse leadership experience, including influencing and collaborating with peers, developing and coaching others, and overseeing and guiding colleagues’ work to achieve meaningful outcomes and business impact.
  • The candidate must be able to coordinate and execute clinical development or lifecycle strategy and understand complexities and recent developments in the principal disease areas, as well as scientific, mechanistic, commercial, and regulatory aspects of drug development.
  • The candidate must be able to work in a highly complex matrixed environment and influence cross-functional teams.
  • The candidate must be an effective leader of staff and able to manage and motivate internal clinical-trial teams.
  • The candidate must be able to mentor and coach others in conflict-management skills and take responsibility for decisions.
  • The candidate must foster team morale, open dialogue, belonging, and accountability for results.
  • Candidates must be authorized to be employed in the United States by any employer, with permanent U.S. work authorization.
Responsibilities
  • Represent Clinical on the Global Medicine Team and serve as the single clinical point of accountability for clinical development for assigned assets in Internal Medicine Research & Development.
  • Lead the cross-functional Clinical Development Team, including clinical, clinical pharmacology, statistics, safety, commercial, patient access, and operations colleagues, in designing, executing, and interpreting studies supporting worldwide regulatory submissions.
  • Create and obtain endorsement for the Clinical Development Plan and associated protocol design documents.
  • Partner with clinical and clinical-operations colleagues throughout the lifecycle of studies for assigned assets.
  • Act as a key partner to external companies supporting Pfizer’s Partner of Choice model.
  • Serve as an internal subject-matter expert in the therapeutic area and clinical drug development.
  • Assume additional clinical leadership responsibilities supporting the Obesity portfolio, including trial design, execution, and reporting for other late-stage assets.
  • Provide specialized medical-monitoring support when required.
  • Lead regulatory-submission efforts and contribute to submission deliverables, including the SCE, SCS, and clinical overview.
  • Provide input for target product profiles and regulatory activities, including product labels, core data sheets, Investigator Brochures, Development Safety Update Reports, and Periodic Benefit-Risk Evaluation Reports.
  • Partner with the Medicine Team Lead to negotiate tradeoffs and milestones and deliver the clinical program within agreed timelines and budget.
  • Develop a comprehensive clinical development plan to secure global approval and reimbursement, including in China and Japan.
  • Create the pediatric investigation plan or pediatric study plan and associated protocol design documents with trial clinicians to ensure feasibility and optimized operational execution.
  • Provide product- and program-specific input for target product profiles.
  • Develop clinical-development enabling strategies, including digital, innovation, and patient-engagement approaches.
  • Partner with trial clinicians on governance reviews, including scientific and operational reviews, and provide clinical-development strategy input for assigned studies.
  • Provide therapy-area and indication expertise for clinical review of data, including case-report-form design, signal interpretation, and adverse-event contextualization.
  • Provide specialized medical-monitoring support for individual trial teams when required.
  • Partner with statistics and programming on trial-level statistical analysis plans, table listings and figures, and database release.
  • Develop submission-level deliverables, including IAP, IARP, and submission table listings and figures, and own SCE and SCS deliverables.
  • Support interpretation and communication of clinical-trial data.
  • Review and approve submission-level safety narrative plans.
  • Support product-label development and maintenance.
  • Engage external stakeholders, including advisory boards, steering committees, data monitoring committees, adjudication committees, patients, and patient advocates, to generate strategic insights supporting clinical-development strategy and PDD development.
  • Provide regulatory-submission support for DSUR, PBRER, submission-disclosure deliverables, and product defense.
  • Ensure compliance with internal standard operating procedures and external regulatory standards.
  • Review investigator-initiated research proposals.
Desired Qualifications
  • Demonstrated experience designing and launching large teams is preferred.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose to $15 billion, and non-COVID products grew 5% operationally.
  • Pfizer raised 2026 guidance to $60.5 billion-$62.5 billion after Eliquis, Padcev, Vyndaqel strength.
  • Berobenatide entered Phase 3 planning, giving Pfizer a credible obesity franchise before 2028.

What critics are saying

  • Depo-Provera MDL exceeded 5,800 cases by July 2026, with late-2026 bellwethers looming.
  • Vyndamax still faces Apotex litigation in Delaware, preserving generic-entry uncertainty beyond 2031.
  • Ringaskiddy and Catania cuts show manufacturing contraction, signaling more restructuring through 2029.

What makes Pfizer unique

  • Seagen gives Pfizer leading ADCs: Padcev, Tivdak, Adcetris, Tucysa across oncology.
  • Pfizer still owns COMIRNATY distribution scale, with XFG vaccine approved August 27, 2026.
  • Vyndamax settlement extends U.S. exclusivity to June 1, 2031, stabilizing cardiomyopathy cash flows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.